Boston Scientific Cuts Full-Year EPS Outlook as China Pricing Pressure Extends Into 2027
BSX is trading near its 52-week low of $39.57 (6.5% above the low) on elevated volume (3.6× avg).
Summary
Q3 sales came in at $5.138B, up 1.5%, with adjusted EPS of $0.73 versus $0.75 a year ago. The bigger news is the full-year cut: FY2026 adjusted EPS is now $3.16–3.18 with sales growth of about 4.25%, and Q4 guidance of $0.77–0.79 adjusted EPS sits well below the 84-cent consensus reported yesterday. Management says China pricing pressure will persist into 2027, and weakness in electrophysiology and Watchman may not be offset by Farapulse growth. The $14.5B Penumbra deal now closes in Q1 2027 after regulatory delays, and higher interest rates have raised financing costs, increasing the earnings drag. This follows the October 28 8-K reporting the quarter and the September 8 disclosure that the August cyberattack would materially hit 2026 results — the cyber hit is now layered on top of underlying China and EP softness.
At the time of this announcement, BSX was trading at $42.15 on NYSE in the Life Sciences sector, with a market capitalization of approximately $61.5B. The 52-week trading range was $39.57 to $105.65. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.